AddLife AB (publ) (ALIF_B) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Addlife Ab Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.318 Good morning, everyone, and welcome to the AdLife first quarter presentation. 00:00:05.318 -- 00:00:09.623 Christina and I will take you through the numbers and the highlights of the quarter today. 00:00:09.623 -- 00:00:12.988 Then we will open up for a Q&A, as always. 00:00:12.988 -- 00:00:18.495 And then, as a reminder, I would like to ask you to stay on after the Q&A as well, because, 00:00:18.495 -- 00:00:23.661 as usual, we have a very interesting video of one of our portfolio companies, 00:00:23.661 -- 00:00:25.664 Holmen Halby, that we will be able to show you. 00:00:25.664 -- 00:00:29.751 So now let's dig into the highlights of the first quarter. 00:00:29.751 -- 00:00:35.757 So the companies within AdLife had a great start to 2025. 00:00:35.861 -- 00:00:38.004 We saw significant 00:00:38.004 -- 00:00:43.293 EBITDA margin improvements in both business areas and this is, as you probably remember, 00:00:43.293 -- 00:00:45.307 our highest priority. 00:00:45.307 -- 00:00:48.255 In lab tech, we achieved 12.1% 00:00:48.255 -- 00:00:51.925 EBITDA margin. That's a solid improvement over previous year. 00:00:51.925 -- 00:00:54.893 And in med tech, 13.5%. Almost 00:00:54.893 -- 00:00:57.681 two percentage points improvement over last year. 00:00:57.681 -- 00:01:02.719 So very strong development there. As we talk about the revenue development, 00:01:02.719 -- 00:01:07.645 that was healthy across the board in all geographies and countries. 00:01:07.645 -- 00:01:13.072 We saw slight weakness in the UK, but that was really due to a very big instrument 00:01:13.072 -- 00:01:18.860 order in the previous year. And in general, we are overseeing our product portfolio, 00:01:18.860 -- 00:01:25.148 removing some products that are less profitable...